Numinus Wellness [TSX:NUMI], a Vancouver-based psychedelic drug research firm with a network of Canadian ketamine-therapy clinics, plans to follow its December 16 listing on the main Toronto Stock Exchange (TSX) with a listing on a US exchange in 2022, said Numinus CEO and founder, Payton Nyquvest. “We are aiming to list on a major US…